Cantel Medical taps ex-Cardinal Health vet for CEO Cantel Medical (NYSE:CMD) said today that it named former Cardinal Health (NYSE:CAH) COO George Fotiades to be its new president & CEO, replacing Jorgen Hansen effective immediately. Fotiades will retain his seat on Cantel’s board, the Little Falls, N.J.-based company said. “On behalf of the board, I am very […]
cathworks
Owens & Minor taps former Thermo Fisher CCO Pesicka as prez, CEO | Personnel Moves – February 27, 2019
Owens & Minor (NYSE:OMI) said this month that it named former Thermo Fisher Scientific chief commercial officer Edward Pesicka as its new prez & CEO, effective March 4. Pesicka will replace interim prez & CEO Robert Sledd, who will continue to serve as board chair, the Richmond, Va.-based company said. Prior to his position as chief […]
CathWorks raises $30m in Series C
CathWorks said today that it closed a $30 million Series C round of financing to support its FFRangio non-invasive fractional flow reserve tech. The FFRangio system is designed to provide objective FFR guidance for optimizing percutaneous coronary intervention therapy decisions, the Israel-based company said. FFRangio is derived from routine X-rays during diagnostic angiogram procedures and is […]
Former Rotation Medical CEO Shadan joins Miach Ortho | Personnel Moves – January 3, 2019
Early stage medtech firm Miach Orthopaedics said today that it named former Rotation Medical CEO and medtech vet Martha Shadan as its new prez and chief executive officer. Shadan has held numerous leadership positions at medtech firms, including Zimmer Biomet (NYSE:ZBH), Covidien, Bristol Myers Squibb and Merck, Westborough, Mass.-based Miach said. Prior to joining Miach, Shadan […]
CathWorks wins FDA 510(k) for FFRangio
Non-invasive fractional flow reserve tech developer CathWorks said yesterday that it won FDA 510(k) clearance for its FFRangio non-invasive fractional flow reserve analysis technology. The Israel-based company said that approval came based off of results from the FAST-FFR blinded comparative study study which showed that its FFRangio system was accurate when compared to invasive FFR. “The FDA […]
TCT 2018: Abbott touts low rates of stroke, death in 1-year Portico TAVR study
Abbott (NYSE:ABT) today released one-year results from a study exploring the use of its Portico transcatheter aortic valve replacement system in patients with symptomatic, severe aortic stenosis, touting low rates of stroke, death and leaks between the valve and native heart tissue. Results from the Portico 1 study were presented during a late-breaking session at the Transcatheter […]
CathWorks touts reimbursement win for non-invasive FFR tech
Non-invasive fractional flow reserve tech developer CathWorks said yesterday it won a new CPT code covering its 3D FFRangio non-invasive fractional flow reserve analysis technology. The Israel-based company’s 3D FFRangio technology is now reimbursable when used for the real-time review of possible atherosclerotic stenosis during coronary angiography interventions. The FFRangio tech is designed as a non-invasive FFR […]
Sterilis taps ex-Nanosphere CEO McGarrity as chief exec | Personnel Moves – November 1, 2017
Medical sterilization company Sterilis said yesterday it tapped former Nanosphere (NSDQ:NSPH) chief exec Michael McGarrity as its new CEO. McGarrity held the CEO position at Nanosphere from February 2013 to last June when he oversaw the company’s $76.9 million acquisition by Luminex (NSDQ:LMNX). Prior to his time as head of Nanosphere, McGarrity held positions in sales, marketing […]
CathWorks closes $16m Series B to support non-invasive FFR platform
Non-invasive fractional flow reserve tech developer CathWorks said yesterday it closed a $15.8 million Series B round of financing to support its real-time digital platform designed to determine FFR in cath labs. The round was led by Quark Venture and Triventures and joined by Planven Investments, Pontifax, Corundum Open Innovation, BioStar Ventures and an unnamed […]
